Drug Combination Improved Local Analgesia After Cesarean

Postoperative supplemental opioid analgesic use was approximately 25 mg of morphine equivalents for women in the bupivacaine-ketorolac group, compared with 40 mg for their counterparts in the bupivacaine-only group (P = .020).

None of the women had significant adverse events or study-related complications, and there were no hematomas, infections, or delays in wound healing. One woman developed a subincisional fluid collection.

"The majority of patients we enrolled had had previous cesarean deliveries, which may [have introduced] bias, as patients having second C-sections may respond differently from someone who is undergoing a cesarean for the first time," Dr. Carvalho acknowledged. Additionally, there was some "empiric guessing" involved in the selection of drug doses, and the study focused only on the acute inflammatory period.

"The next plan is to compare systemic versus peripheral administration of various other drugs, and to start understanding the mechanisms behind what is happening in the periphery," he concluded. "We have a very delicate balance where if we inhibit inflammation too much, then we have delayed wound healing. If we accelerate it too much, we might get hypertrophic scarring. So it’s a delicate balance that we can intervene on and maybe improve analgesia, but we mustn’t affect the balance of wound healing."

Dr. Carvalho disclosed that he has a relationship with I-Flow, manufacturer of the pump used in the study.